United Kingdom · Question · Written question
UIN 132785
Nivolumab
Introduced
30 December 2020
Last action
11 January 2021 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
11 January 2021
Summary
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the NICE draft guidance ID681 which recommends that nivolumab is not recommended for the adjuvant treatment of melanoma.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
30 December 2020
Written question
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the NICE draft guidance ID681 which recommends that nivolumab is not recommended for the adjuvant treatment of melanoma.
Source: Commons
11 January 2021
Answer
We have made no such assessment. The National Institute for Health and Care Excellence (NICE) is an independent body and it would not be appropriate for the Department to interfere in the development of NICE’s recommendations While NICE was unable to reco...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2020-12-30/132785
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1273370
- uk · wq-1273370 · source updated 11 January 2021